EZH2 and Leigh syndrome: Thus, this work establishes a preliminary framework for developing a phase I clinical trial using an EZH2 inhibitor as an immunoprevention strategy for patients with LS, either alone or in conjunction with immunization using a neoantigen vaccine, which is currently being pursued in various animal models in the laboratory.